-- Shanghai Haohai Biological Technology (SHA:688366, HKG:6826) reported an attributable profit of 73.6 million yuan for the first quarter of 2026, down 19% from 90.3 million yuan in the year-ago period, according to a Hong Kong bourse filing on Friday.
Hong Kong-listed shares of the ophthalmic products manufacturer were up nearly 2% in late morning trading on Monday.
Earnings per share were 0.32 yuan, compared with 0.39 yuan in the prior year.
Revenue fell 7.6% year on year to 571.4 million yuan, figures showed.